PURPOSE: Conflicting results about the role of genetic variability at IL6, particularly the -174 G/C single nucleotide polymorphism (SNP), in sepsis have been reported. We studied the genetic variability at IL6 in patients with community-acquired pneumonia (CAP) and pneumococcal CAP (P-CAP). METHODS: This was a multicenter, prospective observational study. IL6 -174 was analyzed in 1,227 white Spanish patients with CAP (306 with P-CAP). IL6 1753 C/G (N = 750), 2954 G/C (N = 845), and haplotypes defined by these SNPs were also studied. RESULTS: In CAP patients the genotype -174 GG were associated with protection against acute respiratory distress syndrome (ARDS) (p = 0.008, OR = 0.4, 95% CI 0.2-0.8). No other significant associations were observed. However, in patients with P-CAP multivariate analysis adjusted for age, gender, co-morbidity, hospital of origin, and severity (pneumonia severity index, PSI) showed that the IL6 -174 GG genotype was protective against the development of ARDS (p = 0.002, OR = 0.25, 95% CI 0.07-0.79), septic shock (p = 0.006, OR = 0.46, 95% CI 0.18-0.79), and multiple organ dysfunction syndrome (p = 0.02, OR = 0.53, 95% CI 0.27-0.89). P-CAP patients homozygous for IL6 -174 G also showed a higher survival in a logistic regression analysis adjusted for age, gender, co-morbidity, hospital of origin, and PSI (p = 0.048, OR = 0.27, 95% CI 0.07-0.98). CONCLUSIONS: Our results indicate that the IL-6 -174 GG genotype is associated with lower severity and mortality in patients with P-CAP. This effect was higher than that observed in patients with CAP irrespective of the causal pathogen involved. Our results highlight the importance of the causal pathogen in genetic epidemiological studies in sepsis.
PURPOSE: Conflicting results about the role of genetic variability at IL6, particularly the -174 G/C single nucleotide polymorphism (SNP), in sepsis have been reported. We studied the genetic variability at IL6 in patients with community-acquired pneumonia (CAP) and pneumococcal CAP (P-CAP). METHODS: This was a multicenter, prospective observational study. IL6 -174 was analyzed in 1,227 white Spanish patients with CAP (306 with P-CAP). IL61753 C/G (N = 750), 2954 G/C (N = 845), and haplotypes defined by these SNPs were also studied. RESULTS: In CAP patients the genotype -174 GG were associated with protection against acute respiratory distress syndrome (ARDS) (p = 0.008, OR = 0.4, 95% CI 0.2-0.8). No other significant associations were observed. However, in patients with P-CAP multivariate analysis adjusted for age, gender, co-morbidity, hospital of origin, and severity (pneumonia severity index, PSI) showed that the IL6 -174 GG genotype was protective against the development of ARDS (p = 0.002, OR = 0.25, 95% CI 0.07-0.79), septic shock (p = 0.006, OR = 0.46, 95% CI 0.18-0.79), and multiple organ dysfunction syndrome (p = 0.02, OR = 0.53, 95% CI 0.27-0.89). P-CAP patients homozygous for IL6 -174 G also showed a higher survival in a logistic regression analysis adjusted for age, gender, co-morbidity, hospital of origin, and PSI (p = 0.048, OR = 0.27, 95% CI 0.07-0.98). CONCLUSIONS: Our results indicate that the IL-6 -174 GG genotype is associated with lower severity and mortality in patients with P-CAP. This effect was higher than that observed in patients with CAP irrespective of the causal pathogen involved. Our results highlight the importance of the causal pathogen in genetic epidemiological studies in sepsis.
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Bernhard Schaaf; Jan Rupp; Michael Müller-Steinhardt; Jan Kruse; Florian Boehmke; Matthias Maass; Peter Zabel; Klaus Dalhoff Journal: Cytokine Date: 2005-08-21 Impact factor: 3.861
Authors: Jordi Solé-Violán; M Isabel García-Laorden; José Alberto Marcos-Ramos; Felipe Rodríguez de Castro; Olga Rajas; Luis Borderías; M Luisa Briones; Estefanía Herrera-Ramos; José Blanquer; Javier Aspa; Yanira Florido; Miguel Angel García-Bello; José María Ferrer-Agüero; Ithaisa Sologuren; Carlos Rodriguez-Gallego Journal: Crit Care Med Date: 2011-06 Impact factor: 7.598
Authors: F Burzotta; L Iacoviello; A Di Castelnuovo; F Glieca; N Luciani; R Zamparelli; R Schiavello; M B Donati; A Maseri; G Possati; F Andreotti Journal: Am J Cardiol Date: 2001-11-15 Impact factor: 2.778
Authors: Jordi Solé-Violán; Felipe v de Castro; M Isabel García-Laorden; José Blanquer; Javier Aspa; Luis Borderías; M Luisa Briones; Olga Rajas; Ignacio Martín-Loeches Carrondo; José Alberto Marcos-Ramos; José María Ferrer Agüero; Ayoze Garcia-Saavedra; M Dolores Fiuza; Araceli Caballero-Hidalgo; Carlos Rodriguez-Gallego Journal: Respir Med Date: 2009-11-08 Impact factor: 3.415
Authors: Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia Journal: Antioxid Redox Signal Date: 2019-06-18 Impact factor: 8.401
Authors: Lyubov E Salnikova; Tamara V Smelaya; Arkadiy M Golubev; Alexander V Rubanovich; Viktor V Moroz Journal: Mol Biol Rep Date: 2013-09-26 Impact factor: 2.316
Authors: G Zhang; W Wang; S Li; H Yang; M Zhang; P Zhang; Y Wen; A Wu; L Yang; B Zhou; X Chen Journal: Genes Immun Date: 2015-10-08 Impact factor: 2.676